Gritstone bio, Inc. announced changes to its Board of Directors. Clare Fisher, a talented corporate and business development executive and current svp of business development and mergers & acquisitions at BeiGene, will join the Board effective January 1, 2022. Current member Judith J. Li., partner at Lilly Asia Ventures, will depart the Board effective January 1, 2022. Clare Fisher has over 20 years of experience in healthcare corporate and business development, leading collaborations, licensing, M&A, investments and divestments across many technologies and therapeutic areas. Ms. Fisher currently serves as svp of business development and mergers & acquisitions at BeiGene, a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide.